Technical Analysis for INVA - Innoviva, Inc.

Grade Last Price % Change Price Change
grade B 15.12 0.13% 0.02
INVA closed up 0.13 percent on Friday, February 21, 2020, on 1.32 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical INVA trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Outside Day Range Expansion 0.13%
Overbought Stochastic Strength 0.13%
Pocket Pivot Bullish Swing Setup -0.66%
Overbought Stochastic Strength -0.66%
Up 3 Days in a Row Strength -0.66%
New Uptrend Bullish 0.27%
Upper Bollinger Band Walk Strength 0.27%
Overbought Stochastic Strength 0.27%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.
Medicine Drugs Glucocorticoids Organofluorides

Is INVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.29
52 Week Low 10.03
Average Volume 604,303
200-Day Moving Average 12.91
50-Day Moving Average 14.26
20-Day Moving Average 14.55
10-Day Moving Average 14.95
Average True Range 0.31
ADX 28.05
+DI 25.65
-DI 10.99
Chandelier Exit (Long, 3 ATRs ) 14.42
Chandelier Exit (Short, 3 ATRs ) 14.65
Upper Bollinger Band 15.48
Lower Bollinger Band 13.63
Percent B (%b) 0.8
BandWidth 12.78
MACD Line 0.30
MACD Signal Line 0.26
MACD Histogram 0.0454
Fundamentals Value
Market Cap 1.65 Billion
Num Shares 109 Million
EPS 0.80
Price-to-Earnings (P/E) Ratio 18.90
Price-to-Sales 7.61
Price-to-Book 0.00
PEG Ratio 0.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.51
Resistance 3 (R3) 15.53 15.41 15.45
Resistance 2 (R2) 15.41 15.31 15.41 15.42
Resistance 1 (R1) 15.27 15.25 15.34 15.25 15.40
Pivot Point 15.15 15.15 15.19 15.15 15.15
Support 1 (S1) 15.01 15.05 15.08 14.99 14.84
Support 2 (S2) 14.89 14.99 14.89 14.82
Support 3 (S3) 14.75 14.89 14.80
Support 4 (S4) 14.73